Myriad Genetics, Inc.
MYGN
$4.81
-$0.34-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 71.17% | 91.71% | -330,400.00% | 99.76% | -92.31% |
| Total Depreciation and Amortization | 0.00% | -10.64% | -2.08% | -2.70% | -5.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -48.28% | -95.60% | 1,882.70% | -131.62% | 303.45% |
| Change in Net Operating Assets | -107.48% | 179.26% | -123.14% | 50.00% | -231.51% |
| Cash from Operations | -49.76% | 255.15% | 16.56% | -346.97% | 842.86% |
| Capital Expenditure | -67.86% | 0.00% | 47.17% | -47.22% | -2.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -100.00% |
| Other Investing Activities | 61.76% | 17.07% | -36.67% | -30.43% | -204.55% |
| Cash from Investing | 3.23% | 10.14% | 16.87% | -40.68% | -178.67% |
| Total Debt Issued | -100.00% | -- | -100.00% | 100.00% | 0.00% |
| Total Debt Repaid | 100.50% | -60,000.00% | 99.51% | -7.29% | 4.48% |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -300.00% | -- | 100.00% | -383.33% | 60.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5.95% | -- | -- | -- | -- |
| Cash from Financing | -114.59% | 2,061.54% | -80.88% | 547.62% | 167.74% |
| Foreign Exchange rate Adjustments | -- | -100.00% | 500.00% | 114.29% | -158.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -104.92% | 510.98% | -58.72% | -619.05% | -75.58% |